Substance / Medication

Lenvatinib mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer.
Zhang Yuqing, Zhang Xiaoxin, Lin Lifan et al. · J Clin Endocrinol Metab · 2025
PMID: 39292866Meta-Analysis
Associations Between Obesity and Risk of Thyroid Cancer: A Meta-Analysis of Cohort Studies.
Hisan Urfa Khairatun, Myung Seung-Kwon, Nguyen Giap Viet · Nutr Cancer · 2025
PMID: 39460502Meta-Analysis
A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions.
Shao Junbo, Liu Xingxing, Zhang Geying et al. · Clin Pharmacol Drug Dev · 2024
PMID: 39253868RCT
Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L, Tovoli F, Piscaglia F · Drugs Today (Barc) · 2019
PMID: 31131841Review
[Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment].
Tsuruoka Akihiko, Matsui Junji, Suzuki Takuya et al. · Nihon Yakurigaku Zasshi · 2015
PMID: 26558314Review
Charge-assisted bond and molecular self-assembly drive the gelation of lenvatinib mesylate.
Su Meiling, Pang Zunting, Li Luyuan et al. · Int J Pharm · 2021
PMID: 34416330Other
The mechanism of solvent-mediated desolvation transformation of lenvatinib mesylate from dimethyl sulfoxide solvate to form D.
Zheng Zhixin, Hou Baohong, Cheng Xiaowei et al. · Acta Crystallogr B Struct Sci Cryst Eng Mater · 2020
PMID: 32831255OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lenvatinib mesilate (substance)
SNOMED CT
735068004
UMLS CUI
C2987642

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.